INKT
MiNK Therapeutics, Inc. [INKT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
INKT Stock Summary
In the News
INKT Financial details
Company Rating
-
Market Cap
34.17M
Income
145.76M
Revenue
11.71B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
31
Optionable
No
Shortable
Yes
Earnings
11 May 2024
P/E
0.24
Forward P/E
-
PEG
-0
P/S
-
P/B
-2.57
P/C
-
P/FCF
-2.01
Quick Ratio
0.62
Current Ratio
0.62
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
4.3
EPS next Y
-
EPS next Q
-
EPS this Y
-12.16%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-3.58%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
6.67%
-
-
-
-
SMA20
8.58%
SMA50
37.57%
SMA100
29.52%
Inst Own
-
Inst Trans
-
ROA
1926%
ROE
-2057%
ROC
8.63%
Gross Margin
-21%
Oper. Margin
-
Profit Margin
1%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.75-3.34
52W High
-
52W Low
-
RSI
49.37
Rel Volume
0.06
Avg Volume
104.3K
Volume
6.32K
Perf Week
-0.79%
Perf Month
9.78%
Perf Quarter
27.04%
Perf Half Y
20.38%
-
-
-
-
Beta
0.123
-
-
Volatility
0.3%, 14.3%
Prev Close
2.43%
Price
10.1
Change
4.66%
Company Profile
- Volume Average 104.3K
- Market Capitalization 34.17M
- Employee 31
- CEO Dr. Jennifer S. Buell Ph.D.
- Headquarters New York,NY,US
- IPO Date 2021-10-15
-
Website
https://minktherapeutics.com 
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
